Kerry Group Buys Novozymes, Chr. Hansen Assets for EUR150 Million
By Christian Moess Laursen
Kerry Group has bought assets from Danish biotechnology companies Novozymes and Chr. Hansen for a total consideration of 150 million euros ($161.5 million).
The deal--expected to close in the first half of 2024--comprises certain trade and assets of Chr. Hansen's global lactase enzyme business and the entire share capital of Nuocheng Trillion Food, a Chinese subsidiary of Novozymes.
The Ireland-based food company said Tuesday that the acquisition improves its ability to create biotechnology solutions following acquisitions of c-LEcta and Enmex in 2022 and 2021, respectively.
It is subject to the European Commission's approval of Kerry as a buyer, and forms part of the Novozymes and Chr. Hansen merger-approval process. Earlier today, the executive arm of the EU conditionally approved the merger.
The assets have attributable revenue around EUR40 million in 2022, with sales in more than 50 countries, Kerry Group said.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
December 12, 2023 12:06 ET (17:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results